Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

share with twitter share with LinkedIn share with facebook
share via e-mail
04/20/2018 | 10:29am CEST

Titusville - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that it has entered a new worldwide collaboration with Bristol-Myers Squibb Company on a program to develop and commercialize Factor XIa (FXIa) inhibitors, including BMS-986177, for the prevention and treatment of major thrombotic conditions.

Under the agreement, Janssen Pharmaceuticals, Inc. and Bristol-Myers Squibb Company will advance BMS-986177 into Phase 2 clinical trials and establish a broad development program across multiple therapeutic indications.

The development of novel oral anticoagulants has been a major step forward in the prevention and treatment of thrombosis. The goal for next-generation anticoagulants is to achieve the same efficacy as the current standard of care while substantially lowering the risk of bleeding. Early clinical research has shown that FXIa inhibition has the potential to reduce the risk of thrombotic events with a significantly lower risk of bleeding compared to currently available therapies.

'Janssen has built deep knowledge in the anticoagulation space through our extensive experience researching and developing innovative cardiovascular therapies,' said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular and Metabolism, Janssen Research & Development, LLC. 'We look forward to applying our expertise to this collaboration with Bristol-Myers Squibb to explore the full potential of BMS-986177 through Factor XIa inhibition to provide a wider safety window for anticoagulation than current therapies.'

'With the addition of a Factor XIa inhibitor program to our pipeline, Janssen continues to live up to our long-standing commitment of working tirelessly to bring truly transformational therapies to patients worldwide,' said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. 'With this new collaboration we have the potential to improve the standard of care for patients with cardiovascular conditions characterized by pathologic thrombosis.'

The companies will share development costs and commercial profits and losses. Additional terms of the agreement were not disclosed.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal and www.twitter.com/JanssenUS. Janssen Pharmaceuticals, Inc. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements

This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals, Inc., Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including under 'Item 1A. Risk Factors,' its most recently filed Quarterly Report on Form 10-Q, including under the caption 'Cautionary Note Regarding Forward-Looking Statements,' and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.

Media contact:

Christina Chan

Tel: 908.927.5769

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
04/20JOHNSON & JOHNSON : Janssen Announces Worldwide Development and Commercializatio..
04/19BRISTOL MYERS SQUIBB : Study Findings on Antifungals Are Outlined in Reports fro..
04/19BRISTOL MYERS SQUIBB : and Harvard Announce New Fibrosis Research Collaboration
04/19BRISTOL MYERS SQUIBB : Data on Therapeutics Reported by Researchers at Bristol-M..
04/19BRISTOL MYERS SQUIBB : Myers announces phase 3 CheckMate -141 trial of Opdivo sh..
04/19BRISTOL MYERS SQUIBB : Opdivo gets Priority Review for third-line SCLC
04/18BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Supplemental Bi..
04/18BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo (nivolu..
04/17BRISTOL MYERS SQUIBB : Topples After Merck Treatment Outperforms It In Lung Canc..
04/17BRISTOL MYERS SQUIBB : BMY) Has Fallen To An 8-Month Low On Study Results
More news
News from SeekingAlpha
04/203 THINGS IN BIOTECH, APRIL 19 : Let's Talk Genito-Urinary Cancer 
04/20Key events next week - healthcare 
04/19Novartis Q1 results weigh on pharma stocks 
04/193 THINGS IN BIOTECH, APRIL 18 : Bristol Plows Ahead, Celldex Flops, Alkermes Get.. 
04/18I'm Buying Bristol-Myers Down Near 52-Week Lows 
Financials ($)
Sales 2018 21 799 M
EBIT 2018 5 626 M
Net income 2018 4 991 M
Finance 2018 134 M
Yield 2018 3,15%
P/E ratio 2018 17,24
P/E ratio 2019 14,92
EV / Sales 2018 3,92x
EV / Sales 2019 3,57x
Capitalization 85 512 M
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 23
Average target price 62,0 $
Spread / Average Target 20%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-8.59%342 627
PFIZER0.75%217 064
NOVARTIS-6.21%213 465
ROCHE HOLDING LTD.-12.17%193 713